Johnson & Johnson reports Phase 3 TREMFYA data showing 28% and 27% fistula remission in Crohn’s patients
Johnson & Johnson presented new Phase 3 results from the FUZION study that TREMFYA (guselkumab) achieved combined perianal fistula remission in 28% of patients on the 100 mg every‑8‑weeks regimen and 27% on the 200 mg every‑4‑weeks regimen at Week 24, versus 10% with placebo. Subgroup analyses showed similar benefits across patients with high baseline disease activity, prior biologic exposure, and with or without proctitis. The data were disclosed at the American College of Gastroenterology 2026 Annual Scientific Meeting.
Why it matters
The company says the findings strengthen the case for TREMFYA’s use in a difficult‑to‑treat Crohn’s population, potentially expanding its market share in inflammatory‑bowel‑disease therapy. Investors should note that the results may support higher future sales of TREMFYA for Crohn’s disease, subject to regulatory and payer acceptance.
Key facts
- 1In the overall study, 28% of patients receiving TREMFYA 100 mg subcutaneously every 8 weeks achieved combined fistula remission at Week 24. prnewswire.com
- 227% of patients receiving TREMFYA 200 mg subcutaneously every 4 weeks achieved the same endpoint. prnewswire.com
- 310% of patients on placebo achieved combined fistula remission. prnewswire.com
- 4Remission rates for patients with prior biologic exposure were 21% (100 mg) and 29% (200 mg) versus 5% with placebo. prnewswire.com
- 5Patients with CDAI ≥ 220 showed remission rates of 30% (100 mg) and 21% (200 mg) versus 0% with placebo. prnewswire.com
- 6Adverse events were consistent with TREMFYA’s known safety profile in Crohn’s disease. prnewswire.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.